Regen BioPharma Inc (RGBP)

[Carter]

They don't need to start paying it back until March, 2022, right? And it's not some huge sum of money.

The idea here is the IP is valuable, such that RGBP will enter into partnerships/JV's and/or buyout...any of which provides the revenue.

If you don't think partnerships or a buyout is possible/probable, then I guess you'd despair over the payment terms. If you do think it's probable (as many here do, including me), then it's not a big deal.

Comes down to what you think of the IP and prospects of Regen monetizing it in some way over the coming months, IMO.

It comes down to the value of the IP.